IS7170A - Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra - Google Patents

Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra

Info

Publication number: IS7170A
Authority: IS; Iceland
Prior art keywords: sup; ibat; treatment; bile acid; benzothiazepines
Prior art date: 2001-09-08

Application number

IS7170A

Other languages

English (en)

Inventor

Starke Ingemar

Ulf Johan Dahlstrom Mikael

Blomberg David

Alenfalk Suzanne

Skjaret Tore

Lemurell Malin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-08

Filing date

2004-03-04

Publication date

2004-03-04

2001-09-08 Priority claimed from GB0121768A external-priority patent/GB0121768D0/en

2002-04-25 Priority claimed from GB0209463A external-priority patent/GB0209463D0/en

2004-03-04 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2004-03-04 Publication of IS7170A publication Critical patent/IS7170A/is

Links

HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 2
239000003613 bile acid Substances 0.000 title abstract 2
KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical class S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 title 1
102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 title 1
101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 title 1
150000007657 benzothiazepines Chemical class 0.000 title 1
238000007443 liposuction Methods 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

IS7170A 2001-09-08 2004-03-04 Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra IS7170A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0121768A GB0121768D0 (en)	2001-09-08	2001-09-08	Chemical compounds
GB0209463A GB0209463D0 (en)	2002-04-25	2002-04-25	Chemical compounds
PCT/GB2002/004033 WO2003022286A1 (en)	2001-09-08	2002-09-05	Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia

Publications (1)

Publication Number	Publication Date
IS7170A true IS7170A (is)	2004-03-04

Family

ID=26246524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7170A IS7170A (is)	2001-09-08	2004-03-04	Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra

Country Status (28)

Country	Link
US (1)	US7132416B2 (is)
EP (1)	EP1427423B9 (is)
JP (2)	JP3616635B2 (is)
KR (1)	KR100935623B1 (is)
CN (1)	CN1582151A (is)
AR (1)	AR037089A1 (is)
AT (1)	ATE349214T1 (is)
AU (1)	AU2002329387B2 (is)
BR (1)	BRPI0212346B1 (is)
CA (1)	CA2459449C (is)
CO (1)	CO5570671A2 (is)
CY (1)	CY1106348T1 (is)
DE (1)	DE60217136T2 (is)
DK (1)	DK1427423T5 (is)
ES (1)	ES2278045T3 (is)
HU (1)	HU227623B1 (is)
IL (2)	IL160691A0 (is)
IS (1)	IS7170A (is)
MX (1)	MXPA04002179A (is)
MY (1)	MY131995A (is)
NO (1)	NO327041B1 (is)
NZ (1)	NZ531796A (is)
PL (1)	PL216023B1 (is)
PT (1)	PT1427423E (is)
RU (1)	RU2305681C2 (is)
TW (1)	TWI331143B (is)
UY (1)	UY27436A1 (is)
WO (1)	WO2003022286A1 (is)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
EG26979A (en)	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
SE0104333D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en) *	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
CA2489834C (en) *	2002-06-20	2006-10-03	Astrazeneca Ab	Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
AU2008202120B2 (en) *	2003-04-05	2009-12-17	Albireo Ab	Use of an IBAT inhibitor for the treatment of prophylaxis of constipation
GB0307918D0 (en) *	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
GB0314131D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
AR057828A1 (es) *	2005-09-29	2007-12-19	Astrazeneca Ab	Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8062824B2 (en)	2006-07-17	2011-11-22	E. I. Du Pont De Nemours And Company	Thermally imageable dielectric layers, thermal transfer donors and receivers
US7528448B2 (en) *	2006-07-17	2009-05-05	E.I. Du Pont De Nemours And Company	Thin film transistor comprising novel conductor and dielectric compositions
PL2125711T3 (pl) *	2007-03-08	2014-05-30	Albireo Ab	Pochodne kwasy 3-fenylopropionowego oraz ich zastosowanie w leczeniu nieswoistego zapalenia jelit
US7666568B2 (en) *	2007-10-23	2010-02-23	E. I. Du Pont De Nemours And Company	Composition and method for providing a patterned metal layer having high conductivity
US7666567B2 (en)	2007-10-23	2010-02-23	E. I. Du Pont De Nemours And Company	Negative imaging method for providing a patterned metal layer having high conductivity
WO2010062861A2 (en)	2008-11-26	2010-06-03	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of obesity and diabetes
ES2552657T3 (es)	2010-05-26	2015-12-01	Satiogen Pharmaceuticals, Inc.	Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
LT3400944T (lt)	2010-11-04	2020-09-25	Albireo Ab	Ibat inhibitoriai, skirt kepenų ligų gydymui
BR112013010705B1 (pt) *	2010-11-08	2020-11-17	Albireo Ab	uso de um inibidor de ibat e um coagulante de ácido biliar, e formulação farmacêutica
US20120114588A1 (en) *	2010-11-08	2012-05-10	Albireo Ab	Ibat inhibitors for treatment of metabolic disorders and related conditions
CN103221051A (zh) *	2010-11-08	2013-07-24	阿尔比里奥公司	用于治疗代谢障碍和相关病症的ibat抑制剂
SG11201401849QA (en)	2011-10-28	2014-05-29	Lumena Pharmaceuticals Inc	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SG10201406155QA (en)	2011-10-28	2014-11-27	Lumena Pharmaceuticals Inc	Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
RU2015139731A (ru)	2013-03-15	2017-04-20	ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи	Ингибиторы рециркуляции желчных кислот для лечения первичного склерозирующего холангита и воспалительного заболевания кишечника
CN105228615A (zh)	2013-03-15	2016-01-06	鲁美纳医药公司	用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
JO3301B1 (ar)	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
KR102560954B1 (ko)	2014-06-25	2023-07-31	이에이 파마 가부시키가이샤	고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
RU2750944C2 (ru)	2016-02-09	2021-07-06	Альбирео Аб	Пероральный состав холестирамина и его применение
RU2750937C2 (ru)	2016-02-09	2021-07-06	Альбирео Аб	Пероральный состав холестирамина и его применение
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
EP3664782B1 (en)	2017-08-09	2025-01-29	Albireo AB	Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
JP2020530448A (ja)	2017-08-09	2020-10-22	アルビレオ・アクチボラグ	コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US10428109B1 (en)	2018-03-09	2019-10-01	Elobix Ab	Process for the preparation of 1,5-benzothiazepine compounds
AU2019232477A1 (en) *	2018-03-09	2020-09-10	Elobix Ab	Process for the preparation of elobixibat
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) *	2018-06-05	2023-06-01	Albireo Ab	Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
PE20210136A1 (es) *	2018-06-20	2021-01-21	Albireo Ab	Formulacion farmaceutica de odevixibat
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US10941127B2 (en)	2019-02-06	2021-03-09	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en)	2019-02-06	2021-04-13	Aibireo AB	Benzothiazepine compounds and their use as bile acid modulators
SMT202300020T1 (it) *	2019-02-06	2023-03-17	Albireo Ab	Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari
CA3127408A1 (en)	2019-02-06	2020-08-13	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
EP3923943B1 (en)	2019-02-12	2024-07-31	Mirum Pharmaceuticals, Inc.	Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
WO2021049311A1 (ja) *	2019-09-09	2021-03-18	エロビクス・アーベー	１，５－ベンゾチアゼピン化合物を製造するための方法
WO2021110885A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothiadiazepine compounds and their use as bile acid modulators
ES2973549T3 (es)	2019-12-04	2024-06-20	Albireo Ab	Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
WO2021110886A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
ES2972045T3 (es)	2019-12-04	2024-06-10	Albireo Ab	Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
PT4069360T (pt)	2019-12-04	2024-03-06	Albireo Ab	Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
TWI877262B (zh)	2019-12-04	2025-03-21	瑞典商艾爾比瑞歐公司	苯并噻氮呯化合物及其作為膽酸調節劑之用途
JP7665620B2 (ja)	2019-12-04	2025-04-21	アルビレオ・アクチボラグ	ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4069361B1 (en)	2019-12-04	2024-01-03	Albireo AB	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110884A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en)	2020-08-03	2022-02-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) *	2020-08-03	2025-03-07	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022101379A1 (en)	2020-11-12	2022-05-19	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
KR20230106651A (ko)	2020-11-12	2023-07-13	알비레오 에이비	진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CA3198216A1 (en)	2020-12-04	2022-06-09	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2022166680A1 (zh) *	2021-06-25	2022-08-11	苏州科睿思制药有限公司	奥德昔巴特的晶型及其制备方法和用途
WO2023174937A1 (en)	2022-03-16	2023-09-21	Sandoz Ag	Particles comprising non-crystalline odevixibat
WO2023203248A1 (en)	2022-04-22	2023-10-26	Albireo Ab	Subcutaneous administration of an asbt inhibitor
CN119343140A (zh)	2022-06-09	2025-01-21	阿尔比里奥公司	治疗肝炎
KR20250029896A (ko)	2022-07-05	2025-03-05	알비레오 에이비	벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도
US20240173333A1 (en)	2022-11-03	2024-05-30	Albireo Ab	Treating Alagille Syndrome (ALGS)
WO2024121431A1 (en)	2022-12-09	2024-06-13	Albireo Ab	Cocrystals of odevixibat
US20240207286A1 (en)	2022-12-09	2024-06-27	Albireo Ab	Asbt inhibitors in the treatment of renal diseases
WO2024184924A1 (en) *	2023-03-06	2024-09-12	Rk Pharma Inc	"an improved process for the preparation of odevixibat and its crystalline forms"
WO2025093760A1 (en)	2023-11-03	2025-05-08	Albireo Ab	Treating pfic2 with odevixibat
WO2025146508A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en)	2024-01-05	2025-07-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4900757A (en)	1988-12-08	1990-02-13	Merrell Dow Pharmaceuticals Inc.	Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
JPH05186357A (ja)	1991-12-31	1993-07-27	Shigeo Ochi	飲食物消化分解産物吸収抑制手段
GB9203347D0 (en)	1992-02-17	1992-04-01	Wellcome Found	Hypolipidaemic compounds
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en)	1994-08-10	1997-02-10	Wellcome Found	Hypolipidaemic compounds.
CN1084741C (zh)	1994-09-13	2002-05-15	孟山都公司	具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬
US5994391A (en)	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en)	1994-11-17	1995-01-04	Wellcom Foundation The Limited	Hypolipidemic benzothiazepines
CN1515567A (zh)	1996-03-11	2004-07-28	G.D.ɪ��˾	具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因
GB9704208D0 (en) *	1997-02-28	1997-04-16	Glaxo Group Ltd	Chemical compounds
IL131872A0 (en)	1997-03-11	2001-03-19	Searle & Co	Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
DE69815180T2 (de)	1997-03-14	2004-04-29	Aventis Pharma Deutschland Gmbh	Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
AUPO763197A0 (en)	1997-06-30	1997-07-24	Sigma Pharmaceuticals Pty Ltd	Health supplement
ES2195428T3 (es)	1997-12-19	2003-12-01	Searle & Co	Metodo para preparar oxidos de tetrahidrobenzotiepina enriquecidos enantiometricamente.
GB9800428D0 (en)	1998-01-10	1998-03-04	Glaxo Group Ltd	Chemical compounds
DE19825804C2 (de)	1998-06-10	2000-08-24	Aventis Pharma Gmbh	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE240120T1 (de)	1998-12-23	2003-05-15	Searle Llc	Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
ES2188285T3 (es)	1998-12-23	2003-06-16	Searle Llc	Combinaciones de inhibidores del transporte de acidos biliares ileales y derivados de acido nicotinico para indicaciones cardiovasculares.
EP1354604A1 (en)	1998-12-23	2003-10-22	G.D. Searle LLC.	Combinations for cardiovascular indications
AU776620B2 (en)	1998-12-23	2004-09-16	G.D. Searle Llc	Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
EA004877B1 (ru)	1998-12-23	2004-08-26	Джи.Ди.Сирл Ллс	Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
JP2002536440A (ja)	1999-02-12	2002-10-29	ジー．ディー．サールエルエルシー	回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規１，２−ベンゾチアゼピン
DE19916108C1 (de)	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv)	1999-04-19	1999-04-19	Astra Ab	New pharmaceutical foromaulations
US6287609B1 (en)	1999-06-09	2001-09-11	Wisconsin Alumni Research Foundation	Unfermented gel fraction from psyllium seed husks
CA2400021A1 (en)	2000-02-18	2001-08-23	Merck & Co., Inc.	Aryloxyacetic acids for diabetes and lipid disorders
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
US20020061888A1 (en)	2000-03-10	2002-05-23	Keller Bradley T.	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2001240115A1 (en)	2000-03-10	2001-09-24	Pharmacia Corporation	Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en)	2000-07-26	2002-12-05	Tremont Samuel J.	Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv)	2000-10-18	2000-10-18	Astrazeneca Ab	Novel formulation
EG26979A (en) *	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
WO2002053548A1 (fr)	2000-12-27	2002-07-11	Banyu Pharmaceutical Co.,Ltd.	Derives de la benzothiazepine
GB0121337D0 (en)	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0201850D0 (en)	2002-01-26	2002-03-13	Astrazeneca Ab	Therapeutic treatment
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en)	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
GB0216321D0 (en)	2002-07-13	2002-08-21	Astrazeneca Ab	Therapeutic treatment
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use

2002
- 2002-09-05 ES ES02765013T patent/ES2278045T3/es not_active Expired - Lifetime
- 2002-09-05 MX MXPA04002179A patent/MXPA04002179A/es active IP Right Grant
- 2002-09-05 AU AU2002329387A patent/AU2002329387B2/en not_active Expired
- 2002-09-05 HU HU0401196A patent/HU227623B1/hu unknown
- 2002-09-05 CN CNA028221133A patent/CN1582151A/zh active Pending
- 2002-09-05 PT PT02765013T patent/PT1427423E/pt unknown
- 2002-09-05 KR KR1020047003407A patent/KR100935623B1/ko not_active Expired - Lifetime
- 2002-09-05 TW TW091120297A patent/TWI331143B/zh not_active IP Right Cessation
- 2002-09-05 DE DE60217136T patent/DE60217136T2/de not_active Expired - Lifetime
- 2002-09-05 WO PCT/GB2002/004033 patent/WO2003022286A1/en not_active Ceased
- 2002-09-05 CA CA2459449A patent/CA2459449C/en not_active Expired - Lifetime
- 2002-09-05 PL PL369078A patent/PL216023B1/pl unknown
- 2002-09-05 US US10/488,870 patent/US7132416B2/en not_active Expired - Lifetime
- 2002-09-05 JP JP2003526415A patent/JP3616635B2/ja not_active Expired - Lifetime
- 2002-09-05 EP EP02765013.4A patent/EP1427423B9/en not_active Expired - Lifetime
- 2002-09-05 DK DK02765013.4T patent/DK1427423T5/da active
- 2002-09-05 MY MYPI20023317A patent/MY131995A/en unknown
- 2002-09-05 RU RU2004110716/04A patent/RU2305681C2/ru active
- 2002-09-05 BR BRPI0212346A patent/BRPI0212346B1/pt not_active IP Right Cessation
- 2002-09-05 IL IL16069102A patent/IL160691A0/xx unknown
- 2002-09-05 AT AT02765013T patent/ATE349214T1/de active
- 2002-09-05 NZ NZ531796A patent/NZ531796A/en not_active IP Right Cessation
- 2002-09-06 UY UY27436A patent/UY27436A1/es not_active IP Right Cessation
- 2002-09-06 AR ARP020103379A patent/AR037089A1/es active IP Right Grant
2004
- 2004-02-16 JP JP2004038919A patent/JP2004210794A/ja active Pending
- 2004-03-02 IL IL160691A patent/IL160691A/en active IP Right Grant
- 2004-03-04 IS IS7170A patent/IS7170A/is unknown
- 2004-03-04 NO NO20040948A patent/NO327041B1/no not_active IP Right Cessation
- 2004-04-06 CO CO04032561A patent/CO5570671A2/es not_active Application Discontinuation
2007
- 2007-03-01 CY CY20071100289T patent/CY1106348T1/el unknown

Also Published As

Publication number	Publication date
MXPA04002179A (es)	2004-06-29
DE60217136D1 (de)	2007-02-08
PT1427423E (pt)	2007-03-30
US20050038009A1 (en)	2005-02-17
PL369078A1 (en)	2005-04-18
TWI331143B (en)	2010-10-01
PL216023B1 (pl)	2014-02-28
BR0212346A (pt)	2004-08-10
AU2002329387B2 (en)	2007-06-07
WO2003022286A1 (en)	2003-03-20
BRPI0212346B1 (pt)	2016-02-02
NO327041B1 (no)	2009-04-06
NO20040948L (no)	2004-03-04
HUP0401196A2 (hu)	2004-10-28
JP3616635B2 (ja)	2005-02-02
RU2305681C2 (ru)	2007-09-10
MY131995A (en)	2007-09-28
HUP0401196A3 (en)	2008-01-28
IL160691A (en)	2011-11-30
RU2004110716A (ru)	2005-05-10
DK1427423T5 (da)	2018-04-09
EP1427423B9 (en)	2017-12-20
UY27436A1 (es)	2003-04-30
EP1427423A1 (en)	2004-06-16
AR037089A1 (es)	2004-10-20
HK1065258A1 (en)	2005-02-18
CA2459449C (en)	2011-02-01
IL160691A0 (en)	2004-08-31
DE60217136T2 (de)	2007-09-27
ATE349214T1 (de)	2007-01-15
JP2004521961A (ja)	2004-07-22
KR20040036935A (ko)	2004-05-03
JP2004210794A (ja)	2004-07-29
NZ531796A (en)	2005-10-28
CA2459449A1 (en)	2003-03-20
HU227623B1 (en)	2011-09-28
CN1582151A (zh)	2005-02-16
ES2278045T9 (es)	2018-04-23
US7132416B2 (en)	2006-11-07
KR100935623B1 (ko)	2010-01-07
ES2278045T3 (es)	2007-08-01
DK1427423T3 (da)	2007-04-02
EP1427423B1 (en)	2006-12-27
CO5570671A2 (es)	2005-10-31
CY1106348T1 (el)	2011-10-12

Publication	Publication Date	Title
IS7170A (is)	2004-03-04	Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra
ATE438634T1 (de)	2009-08-15	Benzothiazepinderivate
UY27435A1 (es)	2003-04-30	Compuestos químicos
NO20032829D0 (no)	2003-06-20	Kjemiske forbindelser
NO20040954L (no)	2004-03-04	Benzotiazepinderivater for behandling av hyperlipidemi
SE0000772D0 (sv)	2000-03-08	Chemical compounds
MY134270A (en)	2007-11-30	Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions
WO2003091232A3 (en)	2003-12-24	Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
GEP20064005B (en)	2006-12-25	Use of novel benzoimidazole derivatives as antiproliferative agents
SE9904176D0 (sv)	1999-11-18	New use
PL1685142T3 (pl)	2008-06-30	Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
SE0101038D0 (sv)	2001-03-23	Novel compounds
WO2003080631A3 (en)	2004-04-15	Plasma carboxypeptidase b inhibitors
EA200001157A2 (ru)	2001-06-25	Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
SE0004811D0 (sv)	2000-12-21	Chemical compounds
SI1501823T1 (sl)	2006-06-30	Novi piperidinil-alkilamino-piridazinonski derivati, postopek za njihovo pripravo in farmacevtski sestavki, ki vsebujejo te spojine